$ETST’s CEO & Chief Science Officer, Dr. Michel Aube stated, “With the funds being raised through the Regulation A+ offering, we will be in a position to begin finalizing all of our projects while we pursue grants from the Canadian government to cover our MSN-2 medical device, CBD patent pending formulas, and CBD based generic pharmaceutical drugs. We would finally be in a position to initiate further studies with University of Montreal as well. I am very excited for 2018 and all that we have coming.”